Dysmenorrhea - Pipeline Review, Q1 2011
Global Markets Direct, March 2011, Pages: 28
Dysmenorrhea - Pipeline Review, Q1 2011
Summary
Global Markets Direct’s, 'Dysmenorrhea - Pipeline Review, Q1 2011', provides an overview of the Dysmenorrhea therapeutic pipeline. This report provides information on the therapeutic development for Dysmenorrhea, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dysmenorrhea. 'Dysmenorrhea - Pipeline Review, Q1 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Dysmenorrhea.
- A review of the Dysmenorrhea products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Dysmenorrhea pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Dysmenorrhea.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Dysmenorrhea pipeline depth and focus of Dysmenorrhea therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Therapeutics Development
An Overview of Pipeline Products for Dysmenorrhea
Dysmenorrhea Therapeutics under Development by Companies
Dysmenorrhea Therapeutics under Investigation by Universities/Institutes
Companies Involved in Dysmenorrhea Therapeutics Development
Columbia Laboratories Inc.
PDC Biotech GmbH
Nobelpharma Co., Ltd.
Vantia Therapeutics
Jiangsu Kanion Pharmaceutical Co., Ltd.
Universities/Institutes Involved in Dysmenorrhea Therapeutics Development
Dysmenorrhea - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles – Companies
NPC-01 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Discontinued Products
Dysmenorrhea - Featured News
1. Mar 26, 2010: Vantia Therapeutics Reveals Structure Of Its Novel Small Molecule Treatment For Dysmenorrhoea, VA111913
2. Sep 18, 2007: Kanion Starts FDA Second Phase Clinical Trial Of Guizhi Fuling Capsule In America
3. Apr 30, 2007: Pfizer Wins Celebrex Patent Decision in Canadian Court, Launch of Generic Product by Novopharm Prohibited until 2014
4. Mar 20, 2007: Pfizer Wins Celebrex Patent Challenge by Generic
5. Feb 23, 2007: Celebrex Label Extended for New Use in Europe.
6. Aug 01, 2005: US FDA Approves New Use for Pfizer's Celebrex For Patients with Ankylosing Spondylitis.
7. Dec 21, 2004: Pfizer Says New NIH Study Results are Consistent with Large Body of Evidence Supporting Cardiovascular Safety of Celebrex
8. Dec 17, 2004: Pfizer Statement on New Information Regarding Cardiovascular Safety of Celebrex
9. Oct 19, 2004: Pfizer to Sponsor Major New Celebrex Clinical Trial
10. May 22, 2003: Pfizer Inc.'s (PFE) Celebrex (Celecoxib Capsules) Linked To Significantly Lower Incidence Of Medication-Induced Damage To The Small Bowel
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Dysmenorrhea, 2011
Products under Development for Dysmenorrhea – Comparative Analysis, 2011
Columbia Laboratories Inc., 2011
PDC Biotech GmbH, 2011
Nobelpharma Co., Ltd., 2011
Vantia Therapeutics, 2011
Jiangsu Kanion Pharmaceutical Co., Ltd., 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Discontinued Products
List of Figures
Number of Products under Development for Dysmenorrhea, 2011
Products under Development for Dysmenorrhea – Comparative Analysis, 2011
Products under Development by Companies, 2011
Products under Investigation by Universities/Institutes, 2011
Assessment by Monotherapy Products, 2011
Assessment by Combination Products, 2011
Assessment by Route of Administration, 2011
Assessment by Stage and Route of Administration, 2011
Assessment by Molecule Type, 2011
Assessment by Stage and Molecule Type, 2011
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
